drugset / Trial / NCT02442362

TOF Versus SOX in Metastatic Gastric Cancer

NCT02442362

Phase 2/3 Completed 60 enrolled The First People's Hospital of Changzhou
RandomizedParallel-groupOpen-labelTreatment

Summary

This study was designed to compare the efficacy and safety of aclitaxel/oxaliplatin/fluorouracil (TOF) regimen and S-1/oxaliplatin (SOX) regimen for metastatic gastric cancer (GC) patients.

Timeline

Start
2012-01
Primary completion
2014-01
Completion
2014-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Oxaliplatin Small molecule 100 mg/m2 Intravenous
Comparator Oxaliplatin Small molecule 130 mg/m2 Intravenous
Comparator Paclitaxel Small molecule 135 mg/m2 Intravenous
Subject S-1 Small molecule 40 mg Oral
Subject S-1 Small molecule 60 mg Oral
Comparator fluorouracil Small molecule 500 mg/m2 Intravenous

Indications